{"id":"menacwy-crm-menveo","safety":{"commonSideEffects":[{"rate":"40–50","effect":"Injection site pain"},{"rate":"10–15","effect":"Injection site erythema"},{"rate":"10–15","effect":"Injection site swelling"},{"rate":"20–30","effect":"Myalgia"},{"rate":"15–25","effect":"Headache"},{"rate":"15–25","effect":"Fatigue"},{"rate":"5–10","effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W, and Y, each conjugated to a diphtheria toxoid carrier protein (CRM197). This conjugation enhances immunogenicity by promoting T-cell dependent B-cell responses, resulting in robust and sustained antibody production against these four serogroups. The induced antibodies provide protection against invasive meningococcal disease caused by these serogroups.","oneSentence":"MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a carrier protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:21.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older"}]},"trialDetails":[{"nctId":"NCT03694405","phase":"PHASE4","title":"Adolescent MenACWY Booster Study","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2018-09-20","conditions":"Meningococcal Disease, Invasive","enrollment":244},{"nctId":"NCT02986854","phase":"PHASE3","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-12-08","conditions":"Infections, Meningococcal","enrollment":704},{"nctId":"NCT02287688","phase":"","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-12-01","conditions":"Meningococcal Disease, Infections, Meningococcal","enrollment":144},{"nctId":"NCT01766206","phase":"PHASE4","title":"Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-03-15","conditions":"Meningococcal Disease","enrollment":3948},{"nctId":"NCT01593514","phase":"PHASE4","title":"Understanding the Immune Response to Two Different Meningitis Vaccines","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2012-12","conditions":"Meningitis, Meningococcal Disease, Septicaemia","enrollment":20},{"nctId":"NCT00616421","phase":"PHASE3","title":"Safety and Immune Response of Novartis of MenACWY Conjugate Vaccine When Given to Healthy Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Meningococcal Infections","enrollment":2907},{"nctId":"NCT01452438","phase":"","title":"Safety Surveillance of MenACWY-CRM Vaccine in Children","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":393},{"nctId":"NCT01452464","phase":"","title":"Safety of MenACWY-CRM Vaccination in Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-09","conditions":"Meningococcal Disease","enrollment":55397},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MenACWY-CRM (Menveo)","genericName":"MenACWY-CRM (Menveo)","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"MenACWY-CRM is a conjugate vaccine that stimulates the immune system to produce antibodies against meningococcal serogroups A, C, W, and Y by linking polysaccharide antigens to a carrier protein. Used for Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y in individuals 2 months of age and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}